Medigen Biotechnology Corp. (3176.TWO)

39.10 +0.40 (+1.03%) At close: 01:30PM CST

Medigen Biotechnology Corp.

No.3, Park Street
14th Floor Nangang District
Taipei 11503
Taiwan
886 2 7736 1234
https://www.medigen.com.tw

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Shun-Lang Chang	General Manager	9.81M	N/A	N/A
Ms. Ya-Ling Chiang	Assistant Vice President of Operations & Management Department	3.04M	N/A	N/A
Ms. Chin-Yen Chen	Assistant Vice President of Drug Development Department	2.54M	N/A	N/A
Ms. Feng-Hua Chen	Finance Manager	N/A	N/A	N/A
Ms. I-Ju Chen	Accounting Manager	N/A	N/A	N/A
Mr. Chieh-Liang Lin	Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.

Corporate governance

Medigen Biotechnology Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.